During regular trading hours, there were many stocks that continued to break up to the upside. These stocks are usually going up with news.If you are looking to day trade also check out my Top 2011 Stock Gainers , Stocks to Buy 2012.You can also check previous stocks to buy reports- Right Here today.Hot stocks Today Right Here.I also have technical analysis different stocks-Right Here. Market Technical analysis Right Here
Quick Look Market Closing Price:
At the close: Dow -1.2% to 12448. S&P -1.46% to 1305. Nasdaq -2.1% to 2814.
Treasurys: 30-year +1.06%. 10-yr +0.23%. 5-yr +0.02%.
Commodities: Crude -0.31% to $92.53. Gold +2.43% to $1573.95.
Currencies: Euro -0.09% vs. dollar. Yen -1.35%. Pound +0.68
After Hours News:
Applied Materials (AMAT): FQ2 EPS of $0.27 beats by $0.03. Revenue of $2.54B (-11.3% Y/Y) beats by $150M. Shares +1.5% AH
Salesforce.com (CRM): FQ1 EPS of $0.37 beats by $0.03. Revenue of $695.5M (+38% Y/Y) beats by $17.3M. Expects FQ2 revenue of $724M-$728M and EPS of $0.38-$0.39, largely above consensus of $713.8M and $0.38. Expects FY13 revenue of $2.97B-$3B and EPS of $1.60-$1.63 vs. consensus of $2.95B and $1.61. Shares +1% AH
Marvell Technology (MRVL): Q1 EPS of $0.23 beats by $0.03. Revenue of $796M (-0.7% Y/Y) beats by $29M. Shares +1.5% AH.
Zumiez (ZUMZ): Q1 EPS of $0.15 beats by $0.04. Revenue of $129.9M (+22.7% Y/Y) in-line. Shares +2.1% AH
Osiris Therapeutics (OSIR) has received marketing approval from Health Canada to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease in children. The approval marks the first time a manufactured stem cell product has been given regulatory clearance and the first therapy approved for the disease. Shares +14% AH
Salesforce.com (CRM): FQ1 EPS of $0.37 beats by $0.03. Revenue of $695.5M (+38% Y/Y) beats by $17.3M. Expects FQ2 revenue of $724M-$728M and EPS of $0.38-$0.39, largely above consensus of $713.8M and $0.38. Expects FY13 revenue of $2.97B-$3B and EPS of $1.60-$1.63 vs. consensus of $2.95B and $1.61. Shares +1% AH
Marvell Technology (MRVL): Q1 EPS of $0.23 beats by $0.03. Revenue of $796M (-0.7% Y/Y) beats by $29M. Shares +1.5% AH.
Zumiez (ZUMZ): Q1 EPS of $0.15 beats by $0.04. Revenue of $129.9M (+22.7% Y/Y) in-line. Shares +2.1% AH
Osiris Therapeutics (OSIR) has received marketing approval from Health Canada to market its stem cell therapy Prochymal for the treatment of acute graft-vs-host disease in children. The approval marks the first time a manufactured stem cell product has been given regulatory clearance and the first therapy approved for the disease. Shares +14% AH
Youku (YOKU): Q1 EPS of -$0.22 misses by $0.03. Revenue of $42.9M (+119% Y/Y) beats by $1.7M. Shares +2.2% AH
Schnitzer Steel's (SCHN) FQ3 market outlook sees nonferrous selling prices increasing 5%-10%, offset by nonferrous volumes which are expected to decline 10%-15% due to high FQ2 production levels. Operating income per ferrous ton expected at $8-$11, ~35% lower Q/Q
Autodesk's FQ1: Though results weren't bad, the CAD software giant is guiding for FQ2 revenue of $580M-$600M and EPS of $0.46-$0.51, largely below a consensus of $600.7M and $0.51. Also, guidance for FY13 revenue growth of 10% is slightly below a 10.4% consensus, and below a long-term target of 12%-14%. FQ1 deferred revenue rose 1% Q/Q and 17% Y/Y to $727M. Americas revenue +14% Y/Y, Asia +19%, EMEA +4%. ADSK -7% AH.
Sequenom (SQNM) says the recently announced provider network participation agreement with Coventry Health Care (CVH) has been terminated without cause by Coventry. The agreement was intended to provide members in the network with coverage for Sequenom CMM's MaterniT21 PLUS laboratory-developed test. SQNM -7.8% AH
Intuit (INTU): FQ3 come in mixed, beating on its EPS but missing on revenue. Net profit rose 6.7% as the company's tax-preparation business posted better revenue during its most critical quarter. The company narrows its FY12 guidance, now expecting $2.92 - $2.97 per share on revenue of $4.2B. Its previous view was for an EPS of $2.90 - $2.97 on revenue between $4.19B - $4.29B. Shares -0.8% AH.
For the latest updates on the stock market, visit,
http://daytradingstock-blog.blogspot.com/
